Clinical Trials · NCT01311518
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Enrollment
- 0
- Start date
- Jul 2019
- Locations
- See registry
- Primary endpoint
- Total MRI infarct zone derived from cardiac MRI scan